Huzel, who participated in the JPMorgan Healthcare Conference as a presenter for the second consecutive year, announced ‘2020 achievements and vision for 2025’ through the Emerging Market track at 9:30 pm (Korean time) on the 13th. Also, during the conference, a 1:1 meeting will be held with major foreign institutional investors.
The presentation will be attended by major executives and staff members including CEO Ji-hoon Son, Vice President of Development Division Chang-jin Lee, and Ji-hye Noh, Executive Vice President of Communication Division.
On this day, Huzel not only maintains its steadfast No. 1 position in the domestic market, but also introduces the competitiveness of a company that has emerged as a global key player as it succeeded in entering the Chinese market. It also discloses the vision for 2025 and the three-year growth strategy from 2021 to 2023 to achieve it.
This year, we plan to focus on the global business vision as we are planning to focus on the global business vision as we are preparing to enter the big market such as obtaining a license to sell botulinum toxin in Europe and submitting a BLA in the US. I plan to announce. Earlier, in October of last year, Huzel obtained the product license for the botulinum toxin formulation Retybo from China, the first in Korea and the fourth in the world.
The blueprint for becoming a global leader in medical aesthetics is also released. As the world’s first company capable of manufacturing and selling all three items of botulinum toxin, HA filler, and lifting thread, the company explains its vision for growth through various R&D pipelines, open innovation strategies, and expansion of production facilities.
An official from Huzel said, “At the JP Morgan Healthcare Conference last year, we announced bold plans such as submitting a Chinese license and BLA in Europe. “We will actively communicate the company’s willingness to move toward value and global players and its growth potential.